Introducing Quadrant Token

Six years ago, my son sustained a serious concussion playing youth hockey. When I took him for testing and treatment, I soon realized that the best that modern medical science had to offer with respect to concussions was little more than educated guesswork. This was not acceptable to me, so I founded Quadrant Biosciences, with the mission of improving how we diagnose, manage and treat concussions.

In late 2017, we released ClearEdge, a data-driven clinical brain health assessment toolkit that brings concussion diagnosis and treatment into the modern age. ClearEdge is already driving dramatic improvement in brain health outcomes: just ask the clinicians, parents, children and families who are using the product. But this is only the beginning: our drive to improve concussion diagnosis and brain health management has led us to amazing discoveries about how epigenentic mechanisms within our bodies provide important signals about the progression and origin of diseases. If we learn how to “decode” these signals, we can drive transformational changes in the way we diagnose and manage some of the most pressing health issues facing our society, including ADHD, Autism Spectrum Disorder and Parkinson’s Disease. These disorders and diseases impose an incalculable toll on families across the world, so if we have an opportunity to fix these problems, we must do everything we can to make it better.

Today, we’re harnessing the power of blockchain technology to take Quadrant Biosciences to the next level. I’m delighted to announce the kick-off of the Quadrant Token Sale, a pioneering security token transaction that will leverage the power of blockchain to provide eligible investors with the opportunity to participate directly in helping us make lives better for children and families. Here’s how it works:

• We’ll be converting all of our outstanding common stock into Quadrant Tokens, which will be ERC-20 tokens on the public Ethereum blockchain. Each Quadrant Token represents one common equity share of the Company, and each Quadrant Token holder will be an owner of our Company. Quadrant Token holders have all of the rights associated with shareholder status, including the right to elect the board of directors and to receive dividends, if and when declared.
• We’ll be selling approximately 20% of the total Quadrant Tokens (approximately 20,000,000 Quadrant Tokens).
• First, approximately 10,000,000 Quadrant Tokens will be sold in private pre-sale transactions.
• Second, the remaining 10,000,000 Tokens will be sold in a web-based Dutch Auction (please see QuadrantToken.com for more information). ETH will be used as the medium of exchange in the Auction.

In sum, the Quadrant Token provides new and exciting opportunities for eligible investors to participate in the ownership and growth of our company, and help us continue to drive pathbreaking scientific discoveries that revolutionize how we diagnose and manage disease.

On a very personal level, I understand what a privilege it is to work with our team, and couldn’t be more excited about what we’re going to accomplish. Please visit QuadrantToken.com for more information about the Quadrant Token Sale, and to sign up to participate in the Auction.

Please join me and the Quadrant Biosciences team in being part of the solution, and help us drive scientific discovery to change the lives of children and families for the better.

Sincerely,

Richard Uhlig, Founder and Chief Executive Office of Quadrant Biosciences